Acquired hemophilia A (AHA) is a severe bleeding disorder caused by inhibiting
autoantibodies to coagulation factor VIII (FVIII). For hemostatic treatment, bypassing agents
and human or porcine FVIII are currently standard of care. Emicizumab is a bispecific, FVIII-
mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital
hemophiliacs. Here, we report on 6 male and 6 female patients with AHA treated with
emicizumab (all data medians and interquartile range), age 74 (64-80) years, initial FVIII< …

Abstract Introduction Acquired haemophilia A (AHA) is a rare and potentially life‐threatening
bleeding disorder arising from autoantibodies that inhibit coagulation factor VIII (FVIII).
Treatment entails achieving haemostasis with bypassing agents or factor replacement, and
eradication of the inhibitor with immunosuppressive therapy (IST). Due to the rarity of AHA,
there are few prospective data to guide management. Methods We present a retrospective
report of 11 AHA patients treated with emicizumab, a FVIII‐mimetic bispecific antibody …